Archive for the ‘Biopsy’ Category

NEW PROSTATE CANCER INFOLINK:  Is more better when it comes to the number of samples taken in a prostate biopsy? Not according to new research. READ MORE>

Read Full Post »

URO TODAY: Men having a biopsy for prostate cancer need to be warned that it will temporarily affect urination and may also have an impact on erectile function, a German study says. READ MORE>

Prostate biopsy causes impaired voiding (of the bladder).

Saturation (20-core) prostate biopsy and periprostatic nerve block seem to have a lasting impact on voiding function.

Erectile function is transiently affected by prostate biopsy regardless of periprostatic nerve block and the number of cores.

Patients who undergo prostate biopsy must be informed about these side effects.

Read Full Post »

URO TODAY: The greater number of positive samples in a prostate cancer biopsy (usually 12 samples), the greater the chance the disease has spread to the lymph system. READ MORE>

The percentage of positive cores involved with prostate cancer is the most reliable predictor of lymph node metastases and indicates the need for extended pelvic lymphadenectomy.

Read Full Post »

URO TODAY: Knowing exactly where in the prostate a biopsy sample has come from is a problem for those diagnosing the disease, but scientists may have found a way to improve that by combining MRI scans with needle biopsy. READ MORE>

It is feasible to document the location of transrectal ultrasonography (TRUS)-guided prostate biopsies on pre-procedure MRI by fusing the pre-procedure TRUS to an endorectal coil MRI using electromagnetic needle tracking.

This procedure may be useful in documenting the location of prior biopsies, improving quality control and thereby avoiding under-sampling of the prostate, as well as directing subsequent biopsies to regions of the prostate not previously sampled.

Read Full Post »

URO TODAY: 5-Alpha reductase inhibitors, such as finasteride and dutasteride, may increase the accuracy of PSA tests in men with elevated or fluctuating PSA levels and previous negative biopsy, according to new data from researchers. READ MORE>

Read Full Post »

URO TODAY: Use of a scale (the T Scale) to rank the seriousness of prostate cancer and thus guide doctors on treatment options has been called into question by new US research. READ MORE>

Analysis of biopsy samples taken from the prostate is not always accurate in determining how far a tumour has spread, a research team says in a paper to the American Urological Association (AUA) annual meeting.

Those with a T2a score have cancer that is confined within the gland and on one side (lobe) only, making them candidates for nerve-sparing surgery and other focal therapy.

“This data suggests that selection of patients who truly have pT2a disease is extremely difficult and may impact [on]successful application of focal therapies,” the researchers say.

The T scale is applied to cancer confined to the prostate and surrounding areas:

TX — Primary tumor cannot be assessed
T0 — No evidence of primary tumor
T1 — Cannot detect tumor with imaging tests
T1a — Less than 5 percent of the prostate is affected by the tumor
T1b — More than 5 percent of the prostate is affected by the tumor
T1c — Tumor identified by needle biopsy, PSA elevated
T2 — Tumor confined within prostate
T2a — Tumor affects one-half of one lobe or less
T2b — Tumor affects more than one-half of one lobe but not both lobes
T2c — Tumor affects both lobes
T3 — Tumor extends through the prostate capsule
T3a — Tumor extends beyond the prostate capsule
T3b — Tumor invades seminal vesicle(s)
T4 — Tumor is fixed or invades surrounding areas, such as the bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall

pT2 — Tumor confined to the prostate
pT2a — Tumor affects one-half of one lobe or less
pT2b — Tumor affects more than one-half of one lobe but not both lobes
pT2c — Tumor affects both lobes
pT3 — Tumor extends beyond the prostate
pT3a — Tumor extends beyond the prostate
pT3b — Tumor invades seminal vesicle(s)
pT4 — Tumor invades the bladder, rectum

Read Full Post »

URO TODAY: The number of positive core samples in a biopsy for prostate cancer appears to be related to how successful hormone therapy will be later. READ MORE>

Our study of 403 patients with an overall mean follow-up of five years supports the concept of a significant association between the proportion of positive biopsy cores and the prognosis of prostate cancer treated by hormonal therapy.

Read Full Post »

NEW PROSTATE CANCER INFO-LINK: Transperineal, template-guided mapping biopsies can find prostate cancer where more traditional 8- or 12-core transrectal ultrasound (TRUS)-guided biopsies often don’t, new research confirms – but is this really an advantage? READ MORE>

Read Full Post »

URO TODAY: Dutch medical scientists have worked out a way to use various medical information – including PSA level – to accurately calculate whether a man needs repeated biopsies for suspected prostate cancer. READ MORE>

An individualized screening algorithm using other available pre-biopsy information in addition to PSA level can result in a considerable reduction of unnecessary biopsies. Very few important prostate cancer cases – for which diagnosis at a subsequent screening visit might be too late for treatment with curative intent – would be missed.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: A new study appears to confirm that transperineal three-dimensional prostate mapping biopsies can be used with a high level of safety to accurately stage appropriately selected prostate cancer patients. READ MORE>

Read Full Post »

Older Posts »